Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01723397 · ClinicalTrials.gov registry record · NA
Effect of Nasaleze on Nasal Challenge With Allergen
A NA study, sponsored by University of Chicago.
- Terminated
- Registry status
- NA
- Development phase
- 14
- Enrollment target
NCT01723397: Clinical Trial NA study, sponsored by University of Chicago.
NCT01723397 is a NA study that was terminated before completion, run by University of Chicago. The registered enrollment target is 14 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01723397, a NA study, was terminated before completion, sponsored by University of Chicago.
- TERMINATED
- Registry status
- NA
- Development phase
- 14 participants
- Enrollment target
Study Summary
The objectives of this protocol are: 1. to confirm the inhibitory effect of Nasaleze on the immediate response to nasal challenge with antigen, and 2. to show that inhibition of the immediate response to nasal challenge with antigen by Nasaleze inhibits subsequent inflammatory events.
Primary Outcome
Change in total nasal symptom score after nasal challenges (the change is calculated as the total nasal symptom score after allergen challenge - total nasal symptom score after diluent challenge) on the second of two days of nasal challenges following one week of pretreatment with Nasaleze or placebo. The nasal symptoms included number of sneezes, symptoms of runny and stuffy nose (separately for each nostril), and itchy nose/throat symptoms. Individual symptoms were score on a scale from 0-3 (0
Interventions
- DRUG Nasaleze Spray
- OTHER Placebo spray
- BIOLOGICAL Allergen
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2012-11 |
| Est. Completion | 2014-07 |
| Phase | NA |
Why NCT01723397 stopped before completion
NCT01723397 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 14 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 3 interventions - of which Nasaleze Spray is the first listed.
NCT01723397 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01723397 about?
NCT01723397 is a clinical study titled "Effect of Nasaleze on Nasal Challenge With Allergen". The objectives of this protocol are: 1. to confirm the inhibitory effect of Nasaleze on the immediate response to nasal challenge with antigen, and 2. to show that inhibition of the immediate response to nasal challenge with antigen by Nasaleze inhibits subsequent inflammatory events.
What is the current status of trial NCT01723397?
This trial is currently terminated. It is a NA study. The enrollment target is 14 participants. The study started on 2012-11. Estimated completion is 2014-07.
What interventions are being tested in trial NCT01723397?
The interventions under investigation include: Nasaleze Spray (DRUG), Placebo spray (OTHER), Allergen (BIOLOGICAL).
Who is sponsoring clinical trial NCT01723397?
This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01723397's enrollment target sits among peer trials
14 1909th of 2000 higher than 90 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02523092 · 14 participants · Phase 4
Use of CXCL9 as a Biomarker of Acthar Efficacy
- NCT04263285 · 14 participants · NA
Treatment of Depression Post-SCI
- NCT04743271 · 14 participants · NA
Food and Circadian Timing
- NCT05065671 · 14 participants · Phase 1
Microbiome Derived Metabolism and Pharmacokinetics
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia